Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
71 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03994211 | Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer | completed | Phase 1 | 25 | BeiGeneINDUSTRY | 4 | Oct 26, 2024 | clinicaltrials |
| NCT05947903 | Validation of the European Oncology Quality of Life Toolkit | unknown | — | 4,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 32 | Aug 20, 2024 | clinicaltrials |
| NCT04799249 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)(PRESERVE 2) | completed | Phase 3 | 194 | G1 Therapeutics, Inc.INDUSTRY | 11 | Aug 1, 2024 | clinicaltrials |
| NCT05573724 | Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 2 | Jun 18, 2024 | clinicaltrials |
| NCT02578797 | A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study | completed | Phase 1 | 45 | Aragon Pharmaceuticals, Inc.INDUSTRY | 5 | Nov 9, 2023 | clinicaltrials |
| NCT02617485 | MabionCD20 Compared to MabThera in Lymphoma Patients(MADILYM) | completed | Phase 3 | 143 | Mabion SAINDUSTRY | 7 | Oct 25, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT02921919 | Open-Label Extension and Safety Study of Talazoparib | completed | Phase 2 | 120 | PfizerINDUSTRY | 9 | Aug 24, 2022 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT02696642 | Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment | completed | Phase 1 | 54 | BayerINDUSTRY | 2 | Jul 9, 2021 | clinicaltrials |
| NCT03077607 | A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors | completed | Phase 1 | 36 | PfizerINDUSTRY | 4 | Jun 30, 2021 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT03123055 | A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-22) | terminated | Phase 1 / Phase 2 | 28 | Rainier TherapeuticsINDUSTRY | 17 | Mar 18, 2020 | clinicaltrials |
| NCT00472303 | A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine | completed | Phase 3 | 622 | Grünenthal GmbHINDUSTRY | 16 | Nov 4, 2019 | clinicaltrials |
| NCT01264887 | Tapentadol in Chronic Malignant Tumour Related Pain | terminated | Phase 3 | 31 | Grünenthal GmbHINDUSTRY | 7 | Nov 4, 2019 | clinicaltrials |
| NCT00910091 | The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | IpsenINDUSTRY | 12 | Jan 30, 2019 | clinicaltrials |
| NCT02225093 | A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer | completed | Phase 1 | 12 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 27, 2017 | clinicaltrials |
| NCT00806819 | Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC | completed | Phase 3 | 718 | Boehringer IngelheimINDUSTRY | 32 | Feb 2, 2017 | clinicaltrials |
| NCT02064829 | Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer(TRIBECA) | completed | N/A | 111 | Sorrento Therapeutics, Inc.INDUSTRY | 7 | Mar 25, 2016 | clinicaltrials |
| NCT02144272 | Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis | completed | Phase 1 | 41 | Eli Lilly and CompanyINDUSTRY | 4 | Jul 17, 2015 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials